Articles by David Ripin and Danielle Kuczynski
No posts found.
David Ripin (primary author) joined the Clinton Health Access Initiative (CHAI) in 2007 and is currently the executive vice president of Access programs and chief science officer. Prior to assuming his current role, he led CHAI’s Pharmaceutical Sciences Team, which conducts research and development work. These efforts focus on reducing the cost of key drugs through recommending formulation, manufacturing process and sourcing improvements, as well as conducting the transfer of these processes to manufacturing partners. Ripin is actively involved in setting international priorities for HIV drug optimization work, including organizing the Conference on Antiretroviral Drug Optimization in 2009. Before joining CHAI, he worked at Pfizer Inc. for 10 years as part of the research and development group, focusing on the commercialization and manufacture of drug candidates. He received a bachelor’s degree in chemistry and Asian studies from the Washington University in St. Louis and earned a Ph.D. in chemistry at Harvard University.
Danielle Kuczynski (supporting author) has been a senior program manager with CHAI since July 2012. She previously managed CHAI’s Health Financing program and now supports its Access team. She has 10 years of experience in international health and has worked at the Center for Global Development, Chemonics International and the University of Toronto’s Center for International Health. Her public sector experience includes serving as a policy analyst for Ontario’s Ministry of Health Promotion. Kuczynski earned a master’s degree in international health policy from London School of Economics and a bachelor’s in psychology and neuroscience.
No posts found.